Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 185-190

  Payne, Miranda J ^a   Argyropoulou, Katerina ^a   Lorigan, Paul ^b   McAleer, James J ^c   Farrugia, David ^d   Davidson, Neville ^e   Kelly, Charles ^f   Chao, David ^g   Marshall, Ernest ^h   Han, Cheng ^a   Wellman, Sandie ^a   Middleton, Mark R ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^e Chelmsford and Essex Centre   (United Kingdom)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THROMBOCYTOPENIA; VERTIGO; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATIENT SELECTION; RECURRENT DISEASE; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERONS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PATIENT SELECTION; PILOT PROJECTS; RECURRENCE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84897018318     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8717     Document Type: Article

References (21)

1. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998-1012, 2004
2. Suojärvi NJ, Jahkola TA, Virolainen S, et al: Outcome following local recurrence or in-transit metastases in cutaneous melanoma. Melanoma Res 22:447-453, 2012
3. Balch CM, Soong SJ, Atkins MB, et al: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131-149, 2004 (Pubitemid 38812179)
4. Leung AM, Hari DM, Morton DL: Surgery for distant melanoma metastasis. Cancer J 18:176-184, 2012
5. Lui P, Cashin R, Machado M, et al: Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treat Rev 33:665-680, 2007 (Pubitemid 350082665)
6. Tawbi HA, Kirkwood JM: Management of metastatic melanoma. Semin Oncol 34:532-545, 2007 (Pubitemid 350236308)
7. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
8. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 12:349-361, 2012
9. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996 (Pubitemid 26019991)
10. Kirkwood JM: Adjuvant interferon in the treatment of melanoma. Br J Cancer 82:1755-1756, 2000
11. Kirkwood JM, Ibrahim J, Lawson DH, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19:1430-1436, 2001 (Pubitemid 32202550)
12. Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670-1677, 2004 (Pubitemid 38435557)
13. Mocellin S, Pasquali S, Rossi CR, et al: Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 102:493-501, 2010
14. Eggermont AM, Suciu S, Testori A, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225, 2012
15. Wheatley K, Ives N, Hancock B, et al: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252, 2003 (Pubitemid 37069655)
16. Mao L, Si L, Chi Z, et al: A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients. Eur J Cancer 47:1498-1503, 2011
17. Pectasides D, Dafni U, Bafaloukos D, et al: Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27:939-944, 2009
18. Agarwala SS, Lee SJ, Flaherty LE, et al: Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol 29:527s, 2011 (suppl; abstr 8505)
19. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001 (Pubitemid 32391207)
20. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000 (Pubitemid 30415832)
21. Corrie P, Marshall A, Goonewardena M, et al: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial. J Clin Oncol 31, 2013 (suppl 18s; abstr LBA9000)